Cargando…

Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes

BACKGROUND: Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. OBJECTIVE: To investigate the effects of vericiguat on QT interval in patients with chronic coronary syn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Böttcher, Michael, Düngen, Hans-Dirk, Corcea, Vasile, Donath, Frank, Fuhr, Rainard, Gal, Pim, Mikus, Gerd, Trenk, Dietmar, Coenen, Martin, Pires, Philippe Vieira, Maschke, Claudia, Aliprantis, Antonios Othon, Besche, Nina, Becker, Corina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006255/ https://www.ncbi.nlm.nih.gov/pubmed/36633816 http://dx.doi.org/10.1007/s40256-022-00557-2

Ejemplares similares

Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study
por: Boettcher, Michael, et al.
Publicado: (2022)

Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study
por: Boettcher, Michael, et al.
Publicado: (2022)

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
por: Ruehs, Hauke, et al.
Publicado: (2023)

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
por: Boettcher, Michael, et al.
Publicado: (2020)

Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults
por: Boettcher, Michael, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
por: Boettcher, Michael, et al.
Publicado: (2020)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
por: Boettcher, Michael, et al.
Publicado: (2020)

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”
por: Boettcher, Michael, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
por: Sahana, Urjosee, et al.
Publicado: (2023)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications
por: Vannuccini, Francesca, et al.
Publicado: (2022)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials
por: Ma, Guofang, et al.
Publicado: (2023)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Impact of vericiguat on baroreflex-mediated sympathetic circulatory regulation: An open-loop analysis
por: Yokoi, Aimi, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy
por: Hu, Bo-ang, et al.
Publicado: (2023)

Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report
por: Speranza-Sánchez, Mario, et al.
Publicado: (2023)

Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)

The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature
por: Meid, Andreas D., et al.
Publicado: (2017)

Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes
por: Malik, Marek, et al.
Publicado: (2018)

Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation
por: Cai, Yun, et al.
Publicado: (2022)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n7d76lursk5kuu5bv3q355o3mn